Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection

Journal of Virology

Volumn 76, Issue 1, 2002, Pages 411-415

  Ortiz, G M ^a   Hu, J ^a   Goldwitz, J A ^a   Chandwani, R ^a   Larsson, M ^a   Bhardwaj, N ^a   Bonhoeffer, S ^a   Ramratnam, B ^a   Zhang, L ^a   Markowitz, M M ^a   Nixon, D F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD8 ANTIGEN; INDINAVIR; LAMIVUDINE; NELFINAVIR; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIREMIA; VIRUS REPLICATION;

ACUTE DISEASE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE COUNT; MALE; VIRAL LOAD;

EID: 0036133259     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.1.411-415.2002     Document Type: Article

References (43)

1. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia
2. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection
3. + T cells produce antiviral cytokines but are impaired in cytolytic function
4. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
5. Skewed maturation of memory HIV-specific CD8 T lymphocytes
6. Pathogenic insights from studies of lymphoid tissue from HIV-infected individuals
7. + responses in HIV type 1-infected patients: Comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy
8. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy
9. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
10. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
11. A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon
12. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children
13. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART)
14. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy
15. Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy
16. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA
17. Stability in the HIV vDNA pool in peripheral CD4+ T cells of untreated patients by single tube quantitative PCR
18. An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytes
19. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
20. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
21. + T cell expansions: Evidence for impaired CTL effector function
22. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals
23. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection
24. Antiretroviral resistance during successful therapy of HIV type 1 infection
25. Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load
26. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
27. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
28. Lymph node architecture preceding and following 6 months of potent antiviral therapy: Follicular hyperplasia persists in parallel with p24 antigen restoration after involution and CD4 cell depletion in an AIDS patient
29. The role of CD4+ T cell help and CD40 ligand in the in vitro expansion of HIV-1-specific memory cytotoxic CD8+ T cell responses
30. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CDB+ and CD4+ T lymphocytes
31. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection
32. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy
33. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
34. + T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency
35. + T cells in chronic human immunodeficiency virus infection
36. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy
37. The impact of early initiation of highly active antiretroviral therapy on the human immunodeficiency virus type 1-specific CD8 T cell response in children
38. Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children
39. Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection
40. Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3æ and CD28, key signaling molecules for T-cell activation
41. CD8+ anti-human immunodeficiency virus suppressor activity (CASA) in response to antiretroviral therapy: Loss of CASA is associated with loss of viremia
42. Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection
43. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy